Literature DB >> 3668805

Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

P Veng-Pedersen1, W R Gillespie.   

Abstract

Disposition decomposition analysis (DDA) is applied to evaluate the rate and extent of drug delivery from the sampling compartment to the peripheral system, i.e., peripheral bioavailability. Four parameters are introduced which are useful in quantifying peripheral bioavailability. The compounded peripheral bioavailability, F comp, is the ratio between the total compounded amount of drug transferred to the peripheral system and the injected dose, D. The AUC peripheral bioavailability, FAUC, is the ratio between the area under the amount vs. time curves for the peripheral system and the sampling compartment. The distribution time td, is the time following an i.v. bolus at which the net transfer of drug to the peripheral system reverses in direction. The maximum peripheral bioavailability, Fmax, is the maximum fraction of an i.v. bolus dose that is present in the peripheral system at any one time. Equations are derived which permit estimation of those parameters from drug concentrations in the sampling compartment. Simple algorithms and a computer program are provided for estimating Fcomp, FAUC, td, Fmax, and other parameters relevant to DDA for drugs that exhibit a linear polyexponential bolus response. Estimates of Ecomp, FAUC, td, and Fmax are presented for several drugs.

Entities:  

Mesh:

Year:  1987        PMID: 3668805     DOI: 10.1007/bf01066323

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  35 in total

1.  Drug-absorption analysis from pharmacological data. I. Method and confirmation exemplified for the mydriatic drug tropicamide.

Authors:  V F Smolen; R D Schoenwald
Journal:  J Pharm Sci       Date:  1971-01       Impact factor: 3.534

2.  Pharmacokinetics of cefamandole using a HPLC assay.

Authors:  N S Aziz; J G Gambertoglio; E T Lin; H Grausz; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

3.  Modeling of drug response in individual subjects.

Authors:  A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

4.  Disposition of synethetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults.

Authors:  S E Tsuei; R G Moore; J J Ashley; W G McBride
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

5.  Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.

Authors:  J W Ward; A McBurney; P R Farrow; P Sharp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Pharmacokinetics of cefroxadin (CGP 9000) in man.

Authors:  A Gerardin; J B Lecaillon; J P Schoeller; G Humbert; J Guibert
Journal:  J Pharmacokinet Biopharm       Date:  1982-02

7.  The pharmacokinetics of furazlocillin in healthy humans.

Authors:  P H Hinderling; U Gundert-Remy; D Förster; W Gau
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

8.  Disposition kinetics of ethambutol in man.

Authors:  C S Lee; D C Brater; J G Gambertoglio; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-08

9.  Pharmacokinetics of intravenous isosorbide-dinitrate.

Authors:  R Platzer; G Reutemann; R L Galeazzi
Journal:  J Pharmacokinet Biopharm       Date:  1982-12

10.  Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function.

Authors:  J T Burke; W A Wargin; R J Sherertz; K L Sanders; M R Blum; F A Sarubbi
Journal:  J Pharmacokinet Biopharm       Date:  1982-12
View more
  6 in total

Review 1.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

2.  Optimal extravascular dosing intervals.

Authors:  P Veng-Pedersen; N B Modi
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

3.  Correction for non-ideal tracer pharmacokinetic disposition by disposition decomposition analysis (DDA).

Authors:  P Veng-Pedersen; S S Hong; J A Widness; R L Schmidt
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

4.  Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? I. General considerations.

Authors:  P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

5.  Drug disposition analysis: a comparison between budesonide and fluticasone.

Authors:  Anders Källén; Lars Thorsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745

6.  Change in erythropoietin pharmacokinetics following hematopoietic transplantation.

Authors:  J A Widness; R L Schmidt; R J Hohl; F D Goldman; N H Al-Huniti; K J Freise; P Veng-Pedersen
Journal:  Clin Pharmacol Ther       Date:  2007-04-11       Impact factor: 6.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.